We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Algorithm Predicts Diabetic Kidney Disease through Blood Tests

By LabMedica International staff writers
Posted on 01 Jun 2023

Diabetes is globally recognized as the main contributor to kidney failure. More...

Notable advancements have been made in devising treatments for kidney disease in diabetic patients. Yet, evaluating an individual's risk for kidney disease based solely on clinical factors can be challenging. Consequently, identifying who is most susceptible to developing diabetic kidney disease is a vital clinical need. Now, scientists have created a computational method that predicts the likelihood of a person with type 2 diabetes developing kidney disease, a common yet severe diabetes complication. This could aid physicians in preventing or improving the management of kidney disease in type 2 diabetes patients.

The new algorithm developed by researchers from Sanford Burnham Prebys (La Jolla, CA, USA) and the Chinese University of Hong Kong (CUHK, Hong Kong) relies on measuring a process known as DNA methylation, which is the accumulation of subtle changes in the DNA. DNA methylation can provide essential insights into gene activation and deactivation and can be easily measured via blood tests.

Utilizing comprehensive data from over 1,200 type 2 diabetes patients registered in the Hong Kong Diabetes Register, the researchers constructed their model which they also tested on an independent group of 326 Native Americans with type 2 diabetes. This confirmed the model's predictive power for kidney disease across diverse populations. The researchers are presently fine-tuning their model and extending its application to address other health and disease-related inquiries, such as why some cancer patients do not respond favorably to certain treatments.

“This study provides a glimpse into the powerful future of predictive diagnostics,” said co-senior author Kevin Yip, Ph.D., a professor and director of Bioinformatics at Sanford Burnham Prebys. “Our team has demonstrated that by combining clinical data with cutting-edge technology, it’s possible to develop computational models to help clinicians optimize the treatment of type 2 diabetes to prevent kidney disease.”

“Our computational model can use methylation markers from a blood sample to predict both current kidney function and how the kidneys will function years in the future, which means it could be easily implemented alongside current methods for evaluating a patient’s risk for kidney disease,” added Yip.

Related Links:
Sanford Burnham Prebys
CUHK 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.